Safety and immunogenicity of hepatitis B vaccine ButaNG in adults

@article{Ioshimoto1999SafetyAI,
  title={Safety and immunogenicity of hepatitis B vaccine ButaNG in adults},
  author={Ioshimoto and Rissato and Bonilha and Miyaki and Raw and Granovski},
  journal={Revista do Instituto de Medicina Tropical de Sao Paulo},
  year={1999},
  volume={41 3},
  pages={191-3}
}
Recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan was administered in two groups of adult volunteers (I, II) following two different schedules of immunization. In the first trial (10 &mgr;g doses and 0, 1, 3 months vaccination schedule) 106 individuals completed the full immunization program. The results of seroconversion by age group varied from 70 to 100% and the GMT from 46.5 to 124.9 mIU mL-1. In the second trial with 68 individuals (for dosage comparison and… CONTINUE READING